BALCHEM CORP
Close on Oct 19, 2026
- Market cap
- $5.49B
- P/E (TTM)
- 33.5
- Dividend yield
- 0.56%
About Balchem
Chemicals & Allied Products, SIC 2800
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across three primary segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company provides nutrient solutions such as choline, mineral amino acid chelates, specialty vitamins, and food systems to food, beverage, and dietary supplement manufacturers. For animal agriculture and companion pets, it supplies microencapsulated nutrients and choline chloride to livestock and feed producers. In its specialty segment, Balchem packages and distributes performance gases, including ethylene oxide for medical device sterilization and fumigants for agricultural processors, alongside foliar crop nutrients for farmers.
The enterprise operates internationally, serving customers through a direct sales team, independent distributors, and sales agents across global markets. Balchem maintains five gas-filling facilities and employs approximately 1,352 full-time workers worldwide, with manufacturing locations in the United States and Europe, including sites in Italy. The corporation maintains its corporate headquarters in Montvale, New Jersey.
Summary of the business section of Balchem's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BALCHEM CORP
- Founded
- 1967
- Headquarters
- Montvale, NJ
- Address
- 5 Paragon Drive 07645
- Phone
- (845) 326-5600
- Website
- balchem.com
- Employees
- 1,352, Dec 31, 2025
- Industry
- Chemicals & Allied Products
- Incorporated in
- Maryland
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, New York, New York
Stock & identifiers
- Ticker
- BCPC
- Exchange
- Nasdaq
- Shares outstanding
- 32M, Jul 23, 2026
- Public float
- $5.14B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-2, Jan 21, 2010; 3-for-2, Jan 22, 2007; 3-for-2, Jan 23, 2006; 3-for-2, Jan 21, 2005; 3-for-2, Jun 4, 1998; 3-for-2, Oct 4, 1994; 4-for-3, Dec 30, 1991; 5-for-4, Dec 31, 1990
- SEC CIK
- 9326
- CUSIP
- 057665200
- ISIN
- US0576652004
- LEI
- 549300VR70OPMHUI3557
- EIN
- 13-2578432
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Theodore L. Harris | Chairman, President & CEO, Director | 94,403 |
| Ren Anthony Gonzalez | SVP and Chief R&D Officer | 7,219 |
| Erin Leigh Gilson | Chief Accounting Officer | 2,486 |
| Gunsteren Job Leonard van | SVP and GM, Specialty Products | 10,149 |
| Hatsuki Miyata | EVP, CLO, & Secretary | 9,232 |
| Frederic Boned | SVP/GM, Human Nutri. & Health | 9,419 |
| Carl Martin Bengtsson | EVP & Chief Financial Officer | 29,012 |
| George Graham | SVP and Chief R&D Officer | 3,220 |
| William A. Backus | VP & Chief Accounting Officer | 7,019 |
| Martin Luther Reid | SVP Chief Supply Chain Officer | 9,615 |
| Michael Brent Tignor | SVP & Chief HR Officer | 12,179 |
| Michael Robert Sestrick | SVP & Chief Technology Officer | 5,610 |
| David B. Fischer | Director | 9,859 |
| Matthew David Wineinger | Director | 8,012 |
| Daniel E. Knutson | Director | 6,899 |
| Monica Vicente | Director | 2,390 |
| Olivier Rigaud | Director | 2,390 |
| Kathleen B. Fish | Director | 3,429 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Ted Harris | $7.89M | $4.92M | $2.35M | $137 | $106 |
| FY2024 Ted Harris | $6.87M | $10.37M | $1.84M | $144 | $103 |
| FY2023 Ted Harris | $5.89M | $10.94M | $1.30M | $131 | $108 |
| FY2022 Ted Harris | $11.95M | $7.98M | $1.19M | $107 | $107 |
| FY2021 Ted Harris | $5.76M | $12.20M | $1.26M | $147 | $124 |
| FY2020 Ted Harris | $4.62M | $5.61M | $1.02M | $114 | $115 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 1,352 full-time employees worldwide, with approximately 16% covered by collective-bargaining agreements.”
Corporate history
Events identified from SEC filings